Antigen-specific enhancement of natural human IgG antibodies to phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol-4-phosphate, cholesterol, and lipid A by a liposomal vaccine containing lipid A

Vaccine

Volumn 29, Issue 32, 2011, Pages 5137-5144

  Matyas, Gary R ^a   Alving, Carl R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Antibodies to lipids; Innate immunity; Liposomes; Monophosphoryl lipid a; Natural antibodies; Polyspecific antibodies

Indexed keywords

CHOLESTEROL; CROSS REACTING ANTIBODY; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; GALACTOSYLCERAMIDE; GANGLIOSIDE GM1; GANGLIOSIDE GM1 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; LIPOSOME; MALARIA VACCINE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE; PHOSPHORYL LIPID A;

ACTIVE IMMUNIZATION; ADSORPTION; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAT SENSITIVITY; HUMAN; HUMAN EXPERIMENT; LIPOSOMAL DELIVERY; MALARIA FALCIPARUM; NONHUMAN; NORMAL HUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ADULT; ANTIGENS; CHOLESTEROL; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; LIPID A; LIPOSOMES; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; PHOSPHATIDYLINOSITOL PHOSPHATES; VACCINATION; VACCINES;

EID: 79960335254     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.042     Document Type: Article

References (56)

1. Guilbert B., Dighiero G., Avrameas S. Naturally occurring antibodies against nine common antigens in human sera I. Detection, isolation and characterization. J Immunol 1982, 128:2779-2787.
2. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 1991, 12:154-159.
3. Lacroix-Desmazes S., Kaveri S.V., Mouthon L., Ayouba A., Malanchère E., Coutinho A., et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 1998, 216:117-137.
4. Notkins A.L. Polyreactivity of antibody molecules. Trends Immunol 2004, 25:174-179.
5. Baumgarth N., Tung J.W., Herzenberg L.A. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin Immunopathol 2005, 26:347-362.
6. Avrameas S., Ternynck T., Tsonis I.A., Lymberi P. Naturally occurring B-cell autoreactivity: a critical overview. J Autoimmun 2007, 29:213-218.
7. Lutz H.U., Binder C.J., Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol 2009, 30:43-51.
8. Wing M.G. The molecular basis for a polyspecific antibody. Clin Exp Immunol 1995, 99:313-315.
9. Cabiedes J., Cabral A.R., Alarcón-Segovia D. Hidden anti-phospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatments. Eur J Immunol 1998, 28:2108-2114.
10. Moss J., Fishman P.H., Richards R.L., Alving C.R., Vaughan M., Brady R.O. Choleragen-mediated release of trapped glucose from liposomes containing ganglioside GM1. Proc Natl Acad Sci USA 1976, 73:3480-3483.
11. Richards R.L., Alving C.R. Immune reactivities of antibodies against glycolipids. Natural antibodies. Cell surface glycolipids. ACS symposium series, no 128 1980, 461-473. American Chemical Society, Washington. C.C. Sweeley (Ed.).
12. Kaise S., Yasuda T., Kasukawa R., Nishimaki T., Watarai S., Tsumita T. Antiglycolipid antibodies in normal and pathologic human sera and synovial fluids. Vox Sang 1985, 49:292-300.
13. Alving C.R., Wassef N.M. Naturally occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism. Immunol Today 1999, 20:362-366.
14. Matyas G.R., Rao M., Pittman P.R., Burge R., Robbins I.E., Wassef N.M., et al. Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice. J Immunol Methods 2004, 286:47-67.
15. Cheng H.M., Phuah E.B. Heat-labile serum inhibitor of anti-phospholipid antibody binding in ELISA. Immunol Lett 1989, 22:263-266.
16. Cheng H.M., Ngeow Y.F., Sam C.K. Heat inactivation of serum potentiates anti-cardiolipin antibody binding in ELISA. J Immunol Methods 1989, 124:235-238.
17. Cheng H.M., Wong K.K. Anti-phospholipid antibody isotypes in normal human sera. Immunol Lett 1990, 23:183-186.
18. Cheng H.M., Chamley L. Cryptic natural autoantibodies and co-potentiators. Autoimmun Rev 2008, 7:431-434.
19. Ochsenbein A.F., Zinkernagel R.M. Natural antibodies and complement link innate and acquired immunity. Immunol Today 2000, 21:624-630.
20. Zhou Z.H., Tzioufas A.G., Notkins A.L. Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J Autoimmun 2007, 29:219-228.
21. Binder C.J., Shaw P.X., Chang M.K., Boullier A., Hartvigsen K., Hörkkö S., et al. The role of natural antibodies in atherogenesis. J Lipid Res 2005, 46:1353-1363.
22. Chen Z.J., Wheeler J., Notkins A.L. Antigen-binding B cells and polyreactive antibodies. Eur J Immunol 1995, 25:579-586.
23. Wang Z., Chen Z.J., Wheeler J., Shen S., Notkins A.L. Characterization of murine polyreactive antigen-binding B cells: presentation of antigens to T cells. Eur J Immunol 2001, 31:1106-1114.
24. Vaarala O., Palosuo T., Kleemola M., Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986, 41:8-15.
25. Asherson R.A., Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003, 62:388-393.
26. Briles D.E., Forman C., Hudak S., Claflin J.L. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med 1982, 156:1177-1185.
27. Navin T.R., Krug E.C., Pearson R.D. Effect of immunoglobulin M from normal human serum on Leishmania donovani promastigote agglutination, complement-mediated killing, and phagocytosis by human monocytes. Infect Immun 1989, 57:1343-1346.
28. Yokota S., Ohtsuka H., Kohzuki T., Noguchi H. A polyreactive human anti-lipid A monoclonal antibody having cross reactivity to polysaccharide portions of Pseudomonas aeruginosa lipopolysaccharides. FEMS Immunol Med Microbiol 1996, 14:31-38.
29. Reid R.R., Prodeus A.P., Khan W., Hsu T., Rosen F.S., Carroll M.C. Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J Immunol 1997, 159:970-975.
30. Boes M., Prodeus A.P., Schmidt T., Carroll M.C., Chen J. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med 1998, 188:2381-2386.
31. Ochsenbein A.F., Fehr T., Lutz C., Suter M., Brombacher F., Hengartner H., et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999, 286:2156-2159.
32. Baumgarth N., Herman O.C., Jager G.C., Brown L.E., Herzenberg L.A., Chen J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med 2000, 192:271-280.
33. Blanco D.R., Champion C.I., Dooley A., Cox D.L., Whitelegge J.P., Faull K., et al. A monoclonal antibody that conveys in vitro killing and partial protection in experimental syphilis binds a phosphorylcholine surface epitope of Treponema pallidum. Infect Immun 2005, 73:3083-3095.
34. Zhou Z.H., Zhang Y., Hu Y.F., Wahl L.M., Cisar J.O., Notkins A.L. The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe 2007, 1:51-61.
35. Boutlis C.S., Riley E.M., Anstey N.M., de Souza J.B. Glycosylphosphatidylinositols in malaria pathogenesis and immunity: potential for therapeutic inhibition and vaccination. Curr Top Microbiol Immunol 2005, 297:145-185.
36. Boutlis C.S., Fagan P.K., Gowda D.C., Lagog M., Mgone C.S., Bockarie M.J., et al. Immunoglobulin G (IgG) responses to Plasmodium falciparum glycosylphosphatidylinositols are short-lived and predominantly of the IgG3 subclass. J Infect Dis 2003, 187:862-865.
37. Schofield L., Hewitt M.C., Evans K., Siomos M.A., Seeberger P.H. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002, 418:785-789.
38. Fries L.F., Gordon D.M., Richards R.L., Egan J.E., Hollingdale M.R., Gross M., et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci USA 1992, 89:358-362.
39. Matyas G.R., Beck Z., Karasavvas N., Alving C.R. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta 2009, 1788:660-665.
40. Karasavvas N., Beck Z., Tong J., Matyas G.R., Rao M., McCutchan F.E., et al. Antibodies induced by liposomal protein exhibit dual binding to protein and lipid epitopes. Biochem Biophys Res Commun 2008, 366:982-987.
41. Alving C.R. Antibodies to liposomes, phospholipids and phosphate esters. Chem Phys Lipids 1986, 40:303-314.
42. Matyas G.R., Wieczorek L., Bansal D., Chenine A.L., Sanders-Buell E., Tovanabutra S., et al. Inhibition of HIV-1 infection of peripheral blood mononuclear cells by a monoclonal antibody that binds to phosphoinositides and induces secretion of β-chemokines. Biochem Biophys Res Commun 2010, 402:808-812.
43. Boyden S.V. Natural antibodies and the immune response. Adv Immunol 1966, 5:1-28.
44. Tiller T., Tsuiji M., Yurasov S., Velinzon K., Nussenzweig M.C., Wardemann H. Autoreactivity in human IgG+ memory B cells. Immunity 2007, 26:205-213.
45. Mouquet H., Scheid J.F., Zoller M.J., Krogsgaard M., Ott R.G., Shukair S., et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010, 467:591-595.
46. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
47. Sánchez-Martínez S., Lorizate M., Hermann K., Kunert R., Basañez G., Nieva J.L. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett 2006, 580:2395-2399.
48. Shen X., Parks R.J., Montefiori D.C., Kirchherr J.L., Keele B.F., Decker J.M., et al. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 2009, 83:3617-3625.
49. Beck Z., Karasavvas N., Matyas G.R., Alving C.R. Membrane-specific antibodies induced by liposomes can simultaneously bind to HIV-1 protein, peptide, and membrane lipid epitopes. J Drug Target 2008, 16:535-542.
50. Matyas G.R., Wieczorek L., Beck Z., Ochsenbauer-Jambor C., Kappes J.C., Michael N.L., et al. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 2009, 23:2069-2077.
51. Martinuc Porobic J., Avcin T., Bozic B., Kuhar M., Cucnik S., Zupancic M., et al. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol 2005, 142:377-380.
52. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6:723-739.
53. Garçon N., Goldman M. Boosting vaccine power. Sci Am 2009, 301(4):72-79.
54. Vandepapelière P., Horsmans Y., Moris P., Van Mechelen M., Janssens M., Koutsoukos M., et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008, 26:1375-1386.
55. Agnandji S.T., Asante K.P., Lyimo J., Vekemans J., Soulanoudjingar S.S., Owusu R., et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 2010, 202:1076-1087.
56. Lusingu J., Olotu A., Leach A., Lievens M., Vekemans J., Olivier A., et al. Safety of the malaria vaccine candidate, RTS S/AS01E in 5 to 17 month old Kenyan and Tanzanian children. PLoS One 2010, 5(11):e14090.